$CNO
CNO Financial Group, Inc. Stock $cno

$cno Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000122460824000041 Filed on May 06, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$1.066B	$1.167B
YoY Change	2.07%	14.3%
Cost Of Revenue	$568.8M	$631.4M
YoY Change	0.51%	3.56%
Gross Profit	$497.4M	$535.1M
YoY Change	3.91%	30.23%
Gross Profit Margin	46.65%	45.87%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$70.40M
YoY Change		7.15%
% of Gross Profit		13.16%
Operating Expenses	$851.6M	$963.8M
YoY Change	-3.96%	2.81%
Operating Profit	$148.6M	$74.80M
YoY Change	83.0%	-2.09%
Interest Expense	$64.20M	-$46.50M
YoY Change	-260.5%	-33.09%
% of Operating Profit	43.2%	-62.17%
Other Income/Expense, Net
YoY Change
Pretax Income	$150.6M	$146.2M
YoY Change	56.71%	-14720.0%
Income Tax	$34.30M	$33.90M
% Of Pretax Income	22.78%	23.19%
Net Earnings	$116.3M	$112.3M
YoY Change	57.8%	-14137.5%
Net Earnings / Revenue	10.91%	9.63%
Basic Earnings Per Share	$1.08	$1.03
Diluted Earnings Per Share	$1.06	$1.01
COMMON SHARES
Basic Shares Outstanding	108.3M shares	109.0M shares
Diluted Shares Outstanding	109.3M shares	110.8M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$992.1M	$649.8M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$27.31B	$26.30B
YoY Change	7.75%	3.79%
Other Assets	$882.8M	$886.1M
YoY Change	-12.34%	-10.32%
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$36.29B	$34.94B
YoY Change	6.57%	2.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$4.523B	$3.896B
YoY Change	13.63%	-3.67%
Other Long-Term Liabilities	$937.6M	$908.8M
YoY Change	4.31%	30.03%
Total Long-Term Liabilities	$5.460B	$4.804B
YoY Change	11.91%	1.29%
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities	$5.460B	$4.804B
Total Liabilities	$33.86B	$32.57B
YoY Change	5.62%	1.84%
SHAREHOLDERS EQUITY
Retained Earnings	$2.095B	$1.996B
YoY Change	21.05%	19.22%
Common Stock	$1.799B	$1.852B
YoY Change	-10.02%	-8.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.429B	$2.368B
YoY Change
Total Liabilities & Shareholders Equity	$36.29B	$34.94B
YoY Change	6.57%	2.72%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$116.3M	$112.3M
YoY Change	57.8%	-14137.5%
Depreciation, Depletion And Amortization		$70.40M
YoY Change		7.15%
Cash From Operating Activities	$110.9M	$94.60M
YoY Change	-21.63%	15.51%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$1.146B	$2.500M
YoY Change	689.19%	-82.01%
Cash From Investing Activities	-$1.146B	-$23.60M
YoY Change	689.19%	-94.2%
FINANCING ACTIVITIES
Cash Dividend Paid		$17.30M
YoY Change		1.17%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.377B	-$310.2M
YoY Change	3066.21%	-253.56%
NET CHANGE
Cash From Operating Activities	110.9M	$94.60M
Cash From Investing Activities	-1.146B	-$23.60M
Cash From Financing Activities	1.377B	-$310.2M
Net Change In Cash	342.3M	-$239.2M
YoY Change	760.05%	94.79%
FREE CASH FLOW
Cash From Operating Activities	$110.9M	$94.60M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109357540	shares
CY2024Q1	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	301900000	usd
CY2023Q1	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	292200000	usd
CY2024Q1	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	167300000	usd
CY2023Q1	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	50800000	usd
CY2024Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-10000000.0	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-14600000	usd
CY2024Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	17800000	usd
CY2023Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	0	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	7800000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-14600000	usd
CY2024Q1	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	51100000	usd
CY2023Q1	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	52100000	usd
CY2024Q1	us-gaap	Revenues Revenues	1156500000	usd
CY2023Q1	us-gaap	Revenues Revenues	1006000000	usd
CY2024Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	631400000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	609700000	usd
CY2024Q1	us-gaap	Liability For Future Policy Benefit Remeasurement Gain Loss LiabilityForFuturePolicyBenefitRemeasurementGainLoss	6400000	usd
CY2023Q1	us-gaap	Liability For Future Policy Benefit Remeasurement Gain Loss LiabilityForFuturePolicyBenefitRemeasurementGainLoss	-600000	usd
CY2024Q1	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	13700000	usd
CY2023Q1	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	-14800000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	60200000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	54700000	usd
CY2024Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	60500000	usd
CY2023Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	55500000	usd
CY2024Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	278300000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	271700000	usd
CY2024Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1010300000	usd
CY2023Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1007000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	146200000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1000000.0	usd
CY2024Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	33900000	usd
CY2023Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	-200000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108964000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114545000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110845000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114545000	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.01
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-114600000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	626100000	usd
CY2024Q1	cno	Other Comprehensive Income Loss Adjustment To Discount Rate For Liability For Future Policy Benefits OtherComprehensiveIncomeLossAdjustmentToDiscountRateForLiabilityForFuturePolicyBenefits	-231700000	usd
CY2023Q1	cno	Other Comprehensive Income Loss Adjustment To Discount Rate For Liability For Future Policy Benefits OtherComprehensiveIncomeLossAdjustmentToDiscountRateForLiabilityForFuturePolicyBenefits	263300000	usd
CY2024Q1	cno	Other Comprehensive Income Loss Adjustment To Specific Credit Risk For Market Risk Benefit OtherComprehensiveIncomeLossAdjustmentToSpecificCreditRiskForMarketRiskBenefit	1400000	usd
CY2023Q1	cno	Other Comprehensive Income Loss Adjustment To Specific Credit Risk For Market Risk Benefit OtherComprehensiveIncomeLossAdjustmentToSpecificCreditRiskForMarketRiskBenefit	-900000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-7300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-10900000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	123000000.0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	374600000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	26500000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	81700000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	96500000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	292900000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	208800000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	292100000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1768800000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	292900000	usd
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	15100000	usd
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16400000	usd
CY2023Q1	cno	Stock Based Compensation StockBasedCompensation	2400000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2031800000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2215600000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	96500000	usd
CY2024Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	40000000.0	usd
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16400000	usd
CY2024Q1	cno	Stock Based Compensation StockBasedCompensation	-300000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2367700000	usd
CY2024Q1	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	582100000	usd
CY2023Q1	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	582200000	usd
CY2024Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	334400000	usd
CY2023Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	315000000.0	usd
CY2024Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	53600000	usd
CY2023Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	50400000	usd
CY2024Q1	cno	Insurance Policy Benefits InsurancePolicyBenefits	408000000.0	usd
CY2023Q1	cno	Insurance Policy Benefits InsurancePolicyBenefits	410900000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	50400000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	38600000	usd
CY2024Q1	cno	Policy Acquisition Costs PolicyAcquisitionCosts	103200000	usd
CY2023Q1	cno	Policy Acquisition Costs PolicyAcquisitionCosts	89800000	usd
CY2024Q1	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	303800000	usd
CY2023Q1	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	320200000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10100000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6200000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	94600000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	81900000	usd
CY2024Q1	cno	Sales Of Investments SalesOfInvestments	671000000.0	usd
CY2023Q1	cno	Sales Of Investments SalesOfInvestments	486500000	usd
CY2024Q1	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	368300000	usd
CY2023Q1	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	276800000	usd
CY2024Q1	cno	Purchases Of Investments PurchasesOfInvestments	1064700000	usd
CY2023Q1	cno	Purchases Of Investments PurchasesOfInvestments	1147700000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	4300000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-8400000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2500000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	13900000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23600000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-406700000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2800000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8100000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	58800000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	25800000	usd
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	17300000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	17100000	usd
CY2024Q1	cno	Payments On Financing Arrangements PaymentsOnFinancingArrangements	3500000	usd
CY2023Q1	cno	Payments On Financing Arrangements PaymentsOnFinancingArrangements	0	usd
CY2024Q1	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	523900000	usd
CY2023Q1	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	498300000	usd
CY2024Q1	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	505500000	usd
CY2023Q1	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	422100000	usd
CY2024Q1	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	222000000.0	usd
CY2023Q1	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	620500000	usd
CY2024Q1	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	222100000	usd
CY2023Q1	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	420400000	usd
CY2024Q1	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	251700000	usd
CY2023Q1	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	39500000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-310200000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	202000000.0	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-239200000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-122800000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	889000000.0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	644900000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	649800000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	522100000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	324800000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	314600000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	2278800000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2175700000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1529800000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1450200000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	12381400000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	10698500000	usd
CY2024Q1	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	16514800000	usd
CY2024Q1	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	14639000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	7436000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	7009100000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	23950800000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	21648100000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1673300000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	21300000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10761400000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1371700000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	12434700000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1393000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1169900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	24500000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10886400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1365000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	12056300000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1389500000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	42900000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	2200000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	-6000000.0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	100000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	39000000.0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	56000000.0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	3000000.0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	800000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	700000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	59100000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	15400000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8000000.0	usd
CY2024Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	1200000	usd
CY2023Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-400000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	16600000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8400000	usd
CY2024Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-10000000.0	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-14600000	usd
CY2024Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-1500000	usd
CY2023Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	1500000	usd
CY2024Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	900000	usd
CY2023Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	400000	usd
CY2024Q1	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	11600000	usd
CY2023Q1	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	1100000	usd
CY2024Q1	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	3800000	usd
CY2023Q1	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	0	usd
CY2024Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	17800000	usd
CY2023Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	0	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	7800000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-14600000	usd
CY2024Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	1200000	usd
CY2023Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-2000000	usd
CY2024Q1	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	1000000	usd
CY2023Q1	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	300000	usd
CY2024Q1	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	4800000	usd
CY2023Q1	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-2500000	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	7800000	usd
CY2024Q1	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	3800000	usd
CY2024Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-1500000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-14600000	usd
CY2023Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	1500000	usd
CY2024Q1	cno	Numberof Investmentsin Defaultor Considered Nonperforming NumberofInvestmentsinDefaultorConsideredNonperforming	0	investment
CY2024Q1	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	197100000	usd
CY2023Q1	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	288500000	usd
CY2024Q1	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2488100000	usd
CY2023Q1	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2593300000	usd
CY2024Q1	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	64700000	usd
CY2023Q1	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	57700000	usd
CY2024Q1	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	195700000	usd
CY2023Q1	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	410500000	usd
CY2024Q1	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	31000000.0	usd
CY2023Q1	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	34700000	usd
CY2024Q1	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	11736500000	usd
CY2023Q1	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	11623300000	usd
CY2023Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-68000000.0	usd
CY2022Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-54000000.0	usd
CY2023Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	4800000	usd
CY2022Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12200000	usd
CY2023Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-63200000	usd
CY2022Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-41800000	usd
CY2024Q1	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	-100000	usd
CY2023Q1	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	100000	usd
CY2024Q1	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	5100000	usd
CY2023Q1	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	5200000	usd
CY2024Q1	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
CY2023Q1	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
CY2024Q1	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
CY2023Q1	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
CY2024Q1	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	-13700000	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	12300000	usd
CY2024Q1	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	-5000000.0	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	5300000	usd
CY2024Q1	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	-1200000	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	-7400000	usd
CY2024Q1	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	1900000	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	600000	usd
CY2024Q1	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	0	usd
CY2023Q1	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	0	usd
CY2024Q1	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	0	usd
CY2023Q1	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	0	usd
CY2024Q1	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	-800000	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	-1400000	usd
CY2024Q1	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-77000000.0	usd
CY2023Q1	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-27100000	usd
CY2024Q1	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	3300000	usd
CY2023Q1	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	13100000	usd
CY2024Q1	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-80300000	usd
CY2023Q1	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-40200000	usd
CY2024Q1	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2023Q1	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2024Q1	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-80300000	usd
CY2023Q1	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-40200000	usd
CY2024Q1	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	84100000	usd
CY2023Q1	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	57800000	usd
CY2024Q1	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	3800000	usd
CY2023Q1	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	17600000	usd
CY2024Q1	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-80300000	usd
CY2023Q1	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-40200000	usd
CY2024Q1	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	46200000	usd
CY2023Q1	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	58900000	usd
CY2024Q1	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P69Y
CY2023Q1	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P68Y
CY2024Q1	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	596900000	usd
CY2023Q1	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	601400000	usd
CY2024Q1	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	120500000	usd
CY2023Q1	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	119400000	usd
CY2024Q1	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	10028600000	usd
CY2023Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9863700000	usd
CY2024Q1	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	10028600000	usd
CY2023Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9863700000	usd
CY2024Q1	us-gaap	Policyholder Funds PolicyholderFunds	15736700000	usd
CY2023Q1	us-gaap	Policyholder Funds PolicyholderFunds	15302900000	usd
CY2024Q1	us-gaap	Policyholder Funds PolicyholderFunds	15736700000	usd
CY2023Q1	us-gaap	Policyholder Funds PolicyholderFunds	15302900000	usd
CY2023Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1851300000	usd
CY2024Q1	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	90600000	usd
CY2024Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	51800000	usd
CY2024Q1	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1890100000	usd
CY2022Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1690400000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	84200000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	46600000	usd
CY2023Q1	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1728000000	usd
CY2023Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	180700000	usd
CY2024Q1	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	5200000	usd
CY2024Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	175500000	usd
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	203700000	usd
CY2023Q1	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	6100000	usd
CY2023Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	197600000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	112300000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	112300000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-800000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-800000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108964000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114545000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1881000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110845000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114545000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2182000	shares
CY2024Q1	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2024Q1	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2024Q1	cno	Segment Revenues SegmentRevenues	1136700000	usd
CY2023Q1	cno	Segment Revenues SegmentRevenues	1000500000	usd
CY2024Q1	cno	Segment Expenses SegmentExpenses	1061900000	usd
CY2023Q1	cno	Segment Expenses SegmentExpenses	924100000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	74800000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	76400000	usd
CY2024Q1	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	17300000	usd
CY2023Q1	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	17800000	usd
CY2024Q1	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	57500000	usd
CY2023Q1	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	58600000	usd
CY2024Q1	us-gaap	Revenues Revenues	1156500000	usd
CY2023Q1	us-gaap	Revenues Revenues	1006000000	usd
CY2024Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1010300000	usd
CY2023Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1007000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	146200000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1000000.0	usd
CY2024Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	33900000	usd
CY2023Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	-200000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2024Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	81000000	usd
CY2024Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	140500000	usd
CY2023Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	20000000.0	usd
CY2024Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	140500000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-44900000	usd
CY2024Q1	us-gaap	Ceded Premiums Written CededPremiumsWritten	46000000	usd
CY2023Q1	us-gaap	Ceded Premiums Written CededPremiumsWritten	48300000	usd
CY2024Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	105800000	usd
CY2023Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	134900000	usd
CY2024Q1	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	4100000	usd
CY2023Q1	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	4100000	usd
CY2024Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	5900000	usd
CY2023Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	4700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1136400000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	35000000.0	usd
CY2024Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	17300000	usd
CY2023Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	14000000.0	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	16600000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-14200000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33900000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.004
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.027
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.232
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.233
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	268300000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	77100000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	42800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	318800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	322800000	usd
CY2024Q1	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	0	usd
CY2023Q4	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	252900000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	419000000.0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	445500000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	47800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	35600000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1096700000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	36300000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	167700000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	163000000.0	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	202700000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	199300000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	894000000.0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	937100000	usd
CY2024Q1	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	-7900000	usd
CY2023Q4	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	-900000	usd
CY2024Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	886100000	usd
CY2023Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	936200000	usd
CY2024Q1	us-gaap	Income Tax Examination Estimate Of Possible Loss IncomeTaxExaminationEstimateOfPossibleLoss	987000000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	894000000	usd
CY2024Q1	cno	Loss Limitation Based On Income Of Life Insurance Company LossLimitationBasedOnIncomeOfLifeInsuranceCompany	0.35
CY2024Q1	cno	Loss Limitation Based On Loss Of Non Life Entities LossLimitationBasedOnLossOfNonLifeEntities	0.35
CY2024Q1	cno	Federal Long Term Tax Exempt Rate FederalLongTermTaxExemptRate	0.0344
CY2024Q1	cno	Ownership Change Threshold Restricting Net Operating Loss Usage OwnershipChangeThresholdRestrictingNetOperatingLossUsage	0.50
CY2024Q1	cno	Nonoperating Loss Carryforwards NonoperatingLossCarryforwards	1277800000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	42800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	9000000.0	usd
CY2023Q4	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	9500000	usd
CY2024Q1	us-gaap	Notes Payable NotesPayable	1141000000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	1140500000	usd
CY2024Q1	cno	Number Of Insurance Subsidiaries That Are Members Of The Federal Home Loan Bank NumberOfInsuranceSubsidiariesThatAreMembersOfTheFederalHomeLoanBank	3	subsidiary
CY2024Q1	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	31400000	usd
CY2023Q1	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	21700000	usd
CY2024Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	40000000	usd
CY2024Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	481800000	usd
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16400000	usd
CY2024Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.15
CY2024Q1	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1267200000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1235200000	usd
CY2024Q1	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-1006300000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-931000000.0	usd
CY2024Q1	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	365100000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	133400000	usd
CY2024Q1	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	3400000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	4800000	usd
CY2024Q1	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	424700000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	451200000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1480300000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1576800000	usd
CY2024Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LITIGATION AND OTHER LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2019, Platinum Partners Value Arbitrage Fund L.P. (in Official Liquidation) ("PPVA"), the Joint Official Liquidators of PPVA (the "JOLs") and Principal Growth Strategies, LLC, ("PGS"), commenced suit against, among others, CNO Financial Group, Inc., Bankers Conseco Life Insurance Company ("BCLIC"), Washington National and 40\|86 Advisors, Inc. (collectively, the "CNO Parties") in Delaware Chancery Court. Plaintiffs seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. Plaintiffs allege that the CNO Parties were unjustly enriched when they terminated BCLIC and Washington National's reinsurance agreements with BRe and recaptured assets from reinsurance trusts, in particular, Agera securities. Plaintiffs contend that the Agera securities were fraudulently transferred to the reinsurance trusts by other Platinum-related entities and they are seeking to claw back those Agera securities, or the value of those assets, from the CNO Parties. The CNO Parties had removed the case to the United States District Court for the District of Delaware but on April 6, 2020, the District Court granted the plaintiff's motion to remand the case back to the Delaware Chancery Court. Plaintiffs have filed an Amended Complaint and the CNO Parties have moved to dismiss the Amended Complaint. The Delaware Chancery Court denied the CNO Parties’ motions to dismiss the Amended Complaint on the basis of forum non conveniens, but granted the CNO Parties’ motion to stay the case pending the conclusion of a related matter. On December 1, 2023, the Delaware Chancery Court lifted the stay as of November 30, 2023. On January 25, 2024, the Delaware Chancery Court granted in part and denied in part the CNO Parties’ motion to dismiss the Amended Complaint. Based on the Court’s ruling, PPVA and the JOLs’ claims against the CNO Parties were dismissed. On April 9, 2024, PGS filed a second amended complaint, which contains the same claims against the CNO Parties that PGS had previously asserted. The CNO Parties are vigorously contesting PGS's claims.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2012, plaintiffs William Jeffrey Burnett and Joe H. Camp commenced an action entitled Burnett v. Conseco Life Ins. Co. against, among others, CNO Financial Group, Inc. and CNO Services, LLC (collectively, the "CNO Entities") in the United States District Court for the Central District of California on behalf of a putative class of former interest-sensitive whole life insurance policyholders who surrendered their policies or let them lapse. Plaintiffs' first amended complaint alleges that the CNO Entities are liable under an alter ego theory for Conseco Life Insurance Company's purported breach of the optional premium payment provision (the "Optional Premium Payment") of plaintiffs' insurance policies. In January 2018, the case was transferred to the United States District Court for the Southern District of Indiana. On August 17, 2020, the Court denied the CNO Entities' motions to dismiss. On January 13, 2021, the Court granted final approval of a class action settlement between plaintiffs and co-defendant Conseco Life Insurance Company (n/k/a Wilco Life Insurance Company). The case remains pending against the CNO Entities. On March 25, 2022, the Court certified a Rule 23(b)(3) class of under 2,000 policyholders who invoked the policy's Optional Premium Payment prior to October 2008 and who surrendered their policies between October 7, 2008 and September 1, 2011. The Court's certification order acknowledged the existence of individualized issues of causation and damages, which the Court stated could be addressed in individualized proceedings following a class trial on the alter ego allegations and the meaning of the subject insurance policy language. The CNO Entities continue to vigorously defend the case.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Examinations and Fines</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div>
CY2022Q1	cno	Number Of Policyholders NumberOfPolicyholders	2000	policyholder
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	70400000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65700000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	23800000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-6400000	usd
CY2024Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	156600000	usd
CY2023Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	173300000	usd
CY2024Q1	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-134800000	usd
CY2023Q1	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-27900000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	103200000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	89800000	usd
CY2024Q1	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	7800000	usd
CY2023Q1	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-14600000	usd
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-22700000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-46800000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	94600000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	81900000	usd
CY2024Q1	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	6100000	usd
CY2023Q1	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	6500000	usd
CY2024Q1	cno	Variable Interest Entity Amortized Cost Securities Held VariableInterestEntityAmortizedCostSecuritiesHeld	547200000	usd
CY2024Q1	cno	Variable Interest Entity Gross Unrealized Gains Fixed Maturity Securities VariableInterestEntityGrossUnrealizedGainsFixedMaturitySecurities	1700000	usd
CY2024Q1	cno	Variable Interest Entity Gross Unrealized Losses Fixed Maturity Securities VariableInterestEntityGrossUnrealizedLossesFixedMaturitySecurities	11200000	usd
CY2024Q1	cno	Variable Interest Entity Fixed Maturity Securities Allowance For Credit Loss VariableInterestEntityFixedMaturitySecuritiesAllowanceForCreditLoss	4300000	usd
CY2024Q1	cno	Variable Interest Entity Fixed Maturity Securities Fair Value VariableInterestEntityFixedMaturitySecuritiesFairValue	533400000	usd
CY2024Q1	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	-3600000	usd
CY2024Q1	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	-6200000	usd
CY2024Q1	cno	Variable Interest Entity Gain Losson Dissolution VariableInterestEntityGainLossonDissolution	3800000	usd
CY2024Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	1200000	usd
CY2024Q1	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	6900000	usd
CY2024Q1	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	81300000	usd
CY2023Q1	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	-600000	usd
CY2023Q1	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	-2600000	usd
CY2023Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-2000000	usd
CY2023Q1	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	800000	usd
CY2023Q1	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	11700000	usd
CY2024Q1	cno	Number Of Investments Held By Variable Interest Entities In Default NumberOfInvestmentsHeldByVariableInterestEntitiesInDefault	0	investment
CY2024Q1	cno	Investments Held In Limited Partnerships InvestmentsHeldInLimitedPartnerships	490400000	usd
CY2024Q1	cno	Unfunded Commitmentsto Limited Partnerships UnfundedCommitmentstoLimitedPartnerships	373100000	usd
CY2024Q1	cno	Fair Value Fixed Maturity Securities Valued Using Broker Quotes Percentage FairValueFixedMaturitySecuritiesValuedUsingBrokerQuotesPercentage	0.93
CY2024Q1	cno	Available For Sale Fixed Maturities With Significant Unobservable Inputs Investment Grade Percent AvailableForSaleFixedMaturitiesWithSignificantUnobservableInputsInvestmentGradePercent	0.72
CY2024Q1	cno	Available For Sale Maturities With Significant Unobservable Inputs Corporate Securities Percent AvailableForSaleMaturitiesWithSignificantUnobservableInputsCorporateSecuritiesPercent	0.85
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
cno-20240331_cal.xml	Edgar Link	unprocessable
cno-20240331_def.xml	Edgar Link	unprocessable
0001224608-24-000041-index-headers.html	Edgar Link	pending
0001224608-24-000041-index.html	Edgar Link	pending
0001224608-24-000041.txt	Edgar Link	pending
0001224608-24-000041-xbrl.zip	Edgar Link	pending
cno-20240331.htm	Edgar Link	pending
cno-20240331.xsd	Edgar Link	pending
cno03312024ex311.htm	Edgar Link	pending
cno03312024ex312.htm	Edgar Link	pending
cno03312024ex321.htm	Edgar Link	pending
cno03312024ex322.htm	Edgar Link	pending
exhibit101-2024elgrestrict.htm	Edgar Link	pending
exhibit102-2024elgpxshares.htm	Edgar Link	pending
exhibit103-2024restricted.htm	Edgar Link	pending
exhibit104-2024pxshares.htm	Edgar Link	pending
exhibit105-creditagreement.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
cno-20240331_lab.xml	Edgar Link	unprocessable
cno-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cno-20240331_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNO
CNO Financial Group, Inc. Stock $cno

2024 Q2 Form 10-Q Financial Statement

#000122460824000041 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO CNO Financial Group, Inc. Stock $cno

2024 Q2 Form 10-Q Financial Statement

#000122460824000041 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO
CNO Financial Group, Inc. Stock $cno